Veru (NASDAQ:VERU) Receives “Buy” Rating from HC Wainwright

Veru (NASDAQ:VERU)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 376.19% from the stock’s current price.

Separately, Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th.

Veru Trading Down 6.0 %

VERU stock opened at $0.63 on Friday. The firm has a market cap of $92.22 million, a PE ratio of -1.31 and a beta of -0.50. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The company has a fifty day simple moving average of $0.74 and a 200 day simple moving average of $0.82.

Veru (NASDAQ:VERU) last released its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. As a group, analysts forecast that Veru will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VERU. Perceptive Advisors LLC raised its stake in shares of Veru by 26.5% in the 2nd quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after buying an additional 1,478,578 shares in the last quarter. PVG Asset Management Corp acquired a new position in Veru in the second quarter worth about $474,000. Bank of New York Mellon Corp lifted its stake in Veru by 1,718.2% during the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after purchasing an additional 419,374 shares during the period. Choreo LLC boosted its holdings in Veru by 261.3% during the second quarter. Choreo LLC now owns 332,050 shares of the company’s stock valued at $292,000 after purchasing an additional 240,134 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Veru in the 2nd quarter valued at approximately $161,000. 47.16% of the stock is owned by institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.